Serum Tumor Markers Have Limited Reliability for Distinguishing Multifocal HCC from Liver Metastases
Serum tumor markers alone cannot reliably distinguish multifocal hepatocellular carcinoma from liver metastases—imaging with multiphasic contrast-enhanced CT or MRI showing characteristic enhancement patterns remains the definitive diagnostic approach. 1, 2
Why Tumor Markers Are Insufficient for This Distinction
AFP (Alpha-Fetoprotein) Limitations
The most recent EASL 2025 guidelines emphasize that AFP is recommended for prognosis after HCC diagnosis is established, not for differential diagnosis 1. Critical limitations include:
- Only 18% of HCC patients have AFP >400 ng/mL, while 46% have normal AFP levels (<20 ng/mL) 2
- AFP lacks specificity: It can be elevated in intrahepatic cholangiocarcinoma, colon cancer metastases, lymphoma, and even benign conditions like chronic hepatitis B/C 2
- Normal AFP does not rule out aggressive HCC 1
DCP (Des-Gamma-Carboxy Prothrombin) Limitations
While DCP shows superior diagnostic accuracy compared to AFP for HCC detection (AUC 0.83 vs 0.77) 3, it has significant technical limitations that preclude reliable use in distinguishing HCC from metastases:
- Cannot be accurately measured in patients with vitamin K deficiency, those on oral anticoagulants, or with poor nutritional status from alcohol abuse 1
- DCP is HCC-specific but doesn't help differentiate multifocal HCC from metastatic disease 4, 5
CEA and CA 19-9 Are Not Useful for This Distinction
These markers are primarily associated with gastrointestinal malignancies:
- CEA and CA 19-9 have poor sensitivity and specificity for HCC diagnosis 6, 7
- Combined AFP, CEA, and CA 19-9 testing shows 100% specificity but only 2.5% sensitivity—making it clinically useless 7
- These markers may be elevated in both HCC and liver metastases from colorectal cancer, providing no discriminatory value 8
The Correct Diagnostic Algorithm
Step 1: Imaging is Primary
Multiphasic contrast-enhanced CT or MRI with characteristic arterial hyperenhancement and washout on portal venous/delayed phases establishes HCC diagnosis 1, 2. This imaging pattern is specific to HCC and distinguishes it from metastases.
Step 2: When Imaging is Inconclusive
- Biopsy is recommended when lesions are suspicious but don't meet imaging criteria for HCC 2
- Multidisciplinary discussion should guide the approach 2
Step 3: Role of Tumor Markers
- Measure AFP after diagnosis for prognostic stratification (AFP >400 ng/mL predicts worse outcomes) 1
- Rising AFP with no visible mass warrants additional imaging studies 2
- Consider AFP and DCP together to improve HCC detection sensitivity to 74.2%, but this still doesn't differentiate HCC from metastases 5
Critical Pitfalls to Avoid
Do not rely on tumor markers alone to distinguish multifocal HCC from metastases—this is a common error that delays appropriate imaging 2
Do not assume elevated CEA/CA 19-9 means metastatic disease—these can be elevated in HCC, particularly cholangiocarcinoma variants 2, 8
Do not dismiss HCC because AFP is normal—up to 46% of HCC patients have normal AFP 2
Do not measure DCP in patients on warfarin or with vitamin K deficiency—results will be unreliable 1
When Tumor Markers Provide Prognostic Value
Once HCC is definitively diagnosed by imaging or biopsy:
- AFP >400 ng/mL predicts worse survival across all systemic therapies and identifies patients who may benefit from ramucirumab after sorafenib failure 1
- High DCP levels correlate with microvascular invasion, poor differentiation, and shorter disease-free survival after resection 4, 5
- Early AFP changes during treatment with atezolizumab-bevacizumab provide prognostic information 1
The bottom line: Imaging characteristics, not serum markers, distinguish multifocal HCC from liver metastases. Use tumor markers for prognosis and monitoring after diagnosis, not for differential diagnosis.